Subthalamic stimulation improves motor function but not home and neighborhood mobility
Funding agencies: This study was supported by Parkinson Society Canada Graduate Student Award (Daneault) and a Canadian Institute of Health Research (CIHR) Doctoral scholarship (Barbat-Artigas). Drs. Duval and Aubertin-Leheudre are supported by a Fonds de la Recherche du Québec-Santé salary grant. This work is also supported by operating grants to Drs. Sadikot and Duval from the CIHR and the Parkinson's Society of Canada
Relevant conflicts of interest/financial disclosures: Drs. Daneault, Barbat-Artigas, Aubertin-Leheudre, Duval, and Sadikot declare that they have no competing interests. Dr. Jodoin received research grants from AbbVie and travel grants from Teva Canada Innovation. Dr. Panisset received research grants from Teva Neuroscience, Novartis, and Allergan. He was a lecturer for Allergan, Merz, Novartis and Teva. He participated in advisory boards for Merck, EMD Serono, Allergan, Merz, Novartis, and Teva.Author roles may be found in the online version of this article.
Author roles may be found in the online version of this article.
Subthalamic (STN) deep brain stimulation (DBS) is a recognized therapy for alleviating motor symptoms of Parkinson's disease (PD). However, little is known about its impact on mobility, an important component of quality of life (QoL). To address this issue, we assessed the impact of STN DBS on life-space mobility and QoL.
Twenty surgical patients with PD were assessed using mobility and QoL scales and the United Parkinson's disease rating scale, and results were compared before surgery and 6 to 9 months postoperatively.
STN DBS significantly improved motor dysfunction but had a limited impact on measures of life-space mobility and QoL.
STN DBS improves motor function and some components of QoL. However, motor recovery does not translate into improved life-space in the intermediate term. In addition to a focus on motor function, multidisciplinary attention to increasing mobility may further improve QoL in the intermediate and long-term. © 2014 International Parkinson and Movement Disorder Society